Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Expert Barred from Testifying About Harm from Accutane Use
In a ruling likely to impact thousands of pending cases, a New Jersey judge has barred Accutane plaintiffs from presenting expert testimony that the drug causes Crohn's disease. The testimony failed to meet the standards of scientific reliability required by New Jersey Rule of Evidence 702, Atlantic County Superior Court Judge Nelson Johnson said in a decision made public Feb. 23. It is one thing to “stand alone in the world of science by advancing a hypothesis that others do not accept,” but “quite another thing to advance a hypothesis that can only be supported by disregarding valid scientific research,” Johnson said.
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.
The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.
Each stage of an attorney's career offers opportunities for a curriculum that addresses both the individual's and the firm's need to drive success.
A defendant in a patent infringement suit may, during discovery and prior to a <i>Markman</i> hearing, compel the plaintiff to produce claim charts, claim constructions, and element-by-element infringement analyses.